English synonyms :(S)-2,3-Bis(tert-butoxycarbonyl)-2,3-diazabicyclo[3.1.1]heptane-4-carboxylic acid
English synonyms:(S)-2,3-Bis(tert-butoxycarbonyl)-2,3-diazabicyclo[3.1.1]heptane-4-carboxylic acid;(S)-2,3-Bis(Boc)-2,3-diazabicyclo[3.1.1]heptane-4-carboxylic acid;(4S)-2,3-bis[(2-methylpropan-2-yl)oxycarbonyl]-2,3-diazabicyclo[3.1.1]heptane-4-carboxylic acid;2,3-Diazabicyclo[3.1.1]heptane-2,3,4-tricarboxylic acid, 2,3-bis(1,1-dimethylethyl) ester, (4S)-
CAS number :3034241-44-3
Molecular formula : C16H26N2O6
Molecular weight :342.39
Properties: White to off-white solid powder
Content: ≥98% Professional scientific accurate detection
Function: Used in foreign trade export, scientific research and chemical reagents and other fields; it is employed mainly as the di-Boc protected form of the bridged bicyclic hydrazine acid (2,3-diazabicyclo[3.1.1]heptane) used as the bridged-ring fragment in the synthesis of RAS(ON) G12V-selective inhibitor RMC-5127 in pharmaceutical research and organic synthesis.
Packing: 1G 100G 500G 1KG
Storage: Dry, sealed, protected from light, stored at 2-8℃, shelf life of 2 years
Structural formula:

(S)-2,3-Bis(tert-butoxycarbonyl)-2,3-diazabicyclo[3.1.1]heptane-4-carboxylic acid use and synthesis method
Intro
(S)-2,3-Bis(tert-butoxycarbonyl)-2,3-diazabicyclo[3.1.1]heptane-4-carboxylic acid (CAS 3034241-44-3) is the di-Boc protected form of a strained bridged-bicyclic hydrazine acid: both adjacent ring nitrogens of the 2,3-diazabicyclo[3.1.1]heptane core are masked as tert-butoxycarbonyl carbamates, while the (4S)-configured bridge carbon bears a free carboxylic acid.
Key identifiers: molecular formula C16H26N2O6, molecular weight 342.39, SMILES CC(C)(C)OC(=O)N1C2CC(C2)[C@H](N1C(=O)OC(C)(C)C)C(O)=O, InChIKey RGCBKLXSJYFGNK-ILDUYXDCSA-N, IUPAC name (4S)-2,3-bis[(2-methylpropan-2-yl)oxycarbonyl]-2,3-diazabicyclo[3.1.1]heptane-4-carboxylic acid. Commercial material is supplied at 98% purity by fine-chemical building block suppliers.
Peculiarity
The compound offers an orthogonal protection pattern: (i) the two adjacent hydrazine nitrogens are held as Boc carbamates, suppressing their reactivity during amide coupling and surviving most non-acidic reaction conditions, with deprotection under mild acid (TFA or HCl/dioxane) releasing the free N-N unit at a late stage; (ii) the free carboxylic acid (pKa 3.76 ± 0.20, predicted) provides a ready handle for standard amide-coupling chemistry; (iii) the rigid bicyclo[3.1.1]heptane core projects all substituents in fixed three-dimensional vectors, and the (4S) stereocentre fixes the absolute configuration. Reported calculated data: boiling point 436.4 ± 47.0°C, density 1.249 ± 0.06 g/cm3 (both predicted values); store sealed and dry at 2-8°C.
Uses
This compound is a synthetic intermediate, not a drug substance, and has no pharmacological activity of its own. It is the di-Boc protected acid form of the characteristic bridged ring of RMC-5127, Revolution Medicines' RAS(ON) G12V-selective inhibitor: the free carboxyl group is coupled to an amine to install the bridged fragment, and the Boc groups are removed at a later step to reveal the N-N hydrazine unit of the active scaffold. Indications and population: RMC-5127 is being developed for advanced (metastatic) KRAS G12V-mutant solid tumours, predominantly pancreatic ductal adenocarcinoma (PDAC), colorectal cancer (CRC) and non-small cell lung cancer (NSCLC); the intended patient population is adults with advanced KRAS G12V-mutant solid tumours who have progressed on, or are intolerant to, prior standard therapies including targeted treatments. KRAS G12V is the second most common oncogenic RAS mutation, with an estimated 48,000 patients diagnosed each year in the United States; the first-in-human Phase 1/1b study dosed its first patient in January 2026 and RMC-5127 remains investigational.
Synthesis and representative transformations
The 2,3-diazabicyclo[3.1.1]heptane ring system is assembled with both adjacent nitrogens protected as Boc carbamates during the ring-forming cyclisation, and the (4S)-configured carboxylic acid is installed at the stereogenic centre of the bridge. The free acid is obtained after conventional work-up and purification. The compound is the direct protected precursor of the methyl (4S)-carboxylate hydrochloride (CAS 3104671-22-6): the two protected forms are interconvertible by standard deprotection, esterification and salt-formation sequences.
Starting materials: protected hydrazine precursors bearing the N-N bond and Boc carbamate protection for ring assembly; the (4S)-carboxyl group is introduced at the bridge stereocentre.
Reagents and conditions: Boc2O (di-tert-butyl dicarbonate) for N-protection; intramolecular cyclisation to form the bicyclo[3.1.1] framework; TFA or HCl/dioxane for late-stage Boc removal; standard amide-coupling reagents (e.g. HATU, EDC/HOBt) for acid activation.
Representative transformations: amide coupling of the free acid with amines; esterification to methyl or ethyl esters; acid-mediated removal of both Boc groups to give the N-N hydrazine salt; elaboration of coupled products towards RAS(ON) inhibitor scaffolds.
Yields and specifications: commercial material is specified at 98% purity; white to off-white solid powder; store sealed and dry at 2-8°C.
Hot Tags: (s)-2,3-bis(tert-butoxycarbonyl)-2,3-diazabicyclo[3.1.1]heptane-4-carboxylic acid, China (s)-2,3-bis(tert-butoxycarbonyl)-2,3-diazabicyclo[3.1.1]heptane-4-carboxylic acid suppliers, active pharmaceutical intermediates, api intermediates, Argatroban Anhydrous Impurities, Dalbavancin HCL, Posaconazole intermediate antifungal drug, Semaglutide side chain

![(S)-2,3-Bis(tert-butoxycarbonyl)-2,3-diazabicyclo[3.1.1]heptane-4-carboxylic Acid](/uploads/42568/s-2-3-bis-tert-butoxycarbonyl-2-35a392.jpg)